July 31, 2016
Spartan Bioscience today launched the world’s smallest commercial molecular diagnostic device, the Spartan Cube, and announced its first applications. About the size of a coffee cup, or four inches cubed, the Cube enables unprecedented portability and convenience, enabling new application in fields such as infectious disease, pharmacogenetics, and food and water safety testing.
The Spartan Cube is a PCR-based platform that fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. In addition, the Cube goes from sample to result in 30 minutes, a fraction of the time compared to lab-based testing.
Spartan today announced three assays: Strep A, Apolipoprotein E (APOE), and Legionella.
July 25, 2016
Spartan Bioscience today announced the first rapid Apolipoprotein E (APOE) genetic test to identify mutations associated with increased risk of late-onset Alzheimer’s disease. The Spartan Cube test provides results in 30 minutes from a patient-friendly non-invasive cheek swab.
The Spartan Cube, the world’s smallest DNA-testing device, is the fastest way to identify patients to enroll in clinical trials or research studies based on their genetics. One-in-four people carry APOE genetic mutations that increase the risk of developing Alzheimer’s. These genetic carriers can be ideal clinical trial candidates, and the Cube can accelerate the identification and enrollment of these patients. For example, the Spartan Cube enables patient testing in doctors’ offices, walk-in clinics or even nursing homes.
Alzheimer’s disease affects more than five million patients in the United States. With an aging baby boomer population, this number will increase significantly, barring a medical breakthrough in treatment or prevention. By 2050, the number of people age 65 and older with Alzheimer's disease may nearly triple from 5.2 million to 13.8 million in the United States alone.
May 31, 2016
Spartan Bioscience today introduced the Spartan Cube, the world’s smallest commercial molecular diagnostics device that enables unprecedented portability and convenience.
The Cube is exceptionally small—it takes up the space of a coffee cup. At only four inches cubed in size, the Cube is portable and fits easily into any space, whether in a hospital, doctor’s office, or pharmacy.
The device’s simple design enables anyone to quickly perform DNA testing. It connects wirelessly to a tablet or laptop that displays test instructions and results with an intuitive touch interface. In addition, the Cube goes from sample to result in a fraction of the time compared to traditional lab-based testing. Doctors, patients, and other users can get immediate results rather than waiting for a lab to run a test.
The Spartan Cube is a PCR-based platform for a variety of molecular diagnostic applications, including infectious disease, pharmacogenetics, and food and water testing. Spartan Bioscience will showcase the Spartan Cube and announce an initial assay menu at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo on July 31, 2016 in Philadelphia, P.A.
Paul Lem, M.D., CEO of Spartan Bioscience, says the Spartan Cube is taking the complexity out of DNA testing.
“The Spartan Cube is a revolutionary molecular diagnostics platform. It enables rapid DNA testing with a device so portable, you can literally hold it in the palm of your hand,” says Dr. Lem. “Whether you want to quickly test a sick patient in a doctor’s office or run a genetic test for drug response—the Spartan Cube will provide results when and where you need them.”
March 18, 2015
Spartan Bioscience today announced that it has received a strategic investment from Canon U.S.A., Inc., a leader in digital imaging solutions. As part of the investment, Seymour Liebman will be joining Spartan’s Board of Directors.
Mr. Liebman is executive vice president, chief administrative officer and general counsel of Canon U.S.A., Inc., senior executive officer of Canon Inc., vice chairman of Canon Solutions America, Inc. and is a member of the Board of Directors of Canon BioMedical, Inc., a recently established wholly-owned subsidiary of Canon U.S.A., Inc.
In addition to the strategic investment, Canon BioMedical and Spartan Bioscience plan to explore areas to work together on the development of future diagnostic products.
October 30, 2014
Spartan Bioscience today announced that Health Canada has approved the Spartan RX CYP2C19 System. It is the first near-patient DNA test for personalized medicine that has been approved in Canada.
August 27, 2013
Spartan Bioscience today announced that the US Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of the Spartan RX CYP2C19 System. It provides genetic results in less than 60 minutes from a non-invasive cheek swab.